The American Lung Association launched a new initiative Monday aimed at increasing biomarker testing for lung cancer, particularly among Black Americans who face disparities in screening and treatment.
The Biomarker, Education, Awareness and Testing (BEAT) Lung Cancer campaign seeks to raise awareness about the importance of biomarker testing, which can help determine the most effective targeted therapies for patients.
“While lung cancer is the leading cause of cancer deaths in the U.S., there has been incredible progress in survival thanks in part to screening, biomarker testing and targeted treatments,” said Harold Wimmer, President and CEO of the American Lung Association.
However, only 4.5% of eligible people are screened for lung cancer. A recent study found 23% of lung cancer patients received chemo and radiation before full biomarker testing.
Black patients are less likely to receive biomarker testing, with only 14% of eligible Black patients tested compared to 26% of white patients. Black men also face higher lung cancer rates and mortality.
The campaign aims to empower Black Americans to discuss biomarker testing and lung cancer screening with their doctors.
See “Closing the Gap: New Campaign Focuses on Increasing Biomarker Testing in High-Risk Communities” (July 16, 2024)
See “Closing the Gap: New Campaign Focuses on Increasing Biomarker Testing in High-Risk Communities” (July 16, 2024)
